TY - JOUR
T1 - Impact van de 18F-DCFPyL PET/CT-scan op het behandeladvies voor patiënten met prostaatkanker en een biochemisch recidief na curatieve therapie
AU - Meijer, Dennie
AU - Ettema, Rosemarijn H.
AU - van Leeuwen, Pim J.
AU - Oosterholt, Pepijn M. J.
AU - Bodar, Yves J. L.
AU - van der Poel, Henk G.
AU - Hendrikse, N. Harry
AU - Donswijk, Maarten L.
AU - Wondergem, Maurits
AU - Vellekoop, Annelies E.
AU - van Moorselaar, R. Jeroen A.
AU - Nieuwenhuijzen, Jakko A.
AU - Oprea-Lager, Daniela E.
AU - Vis, André N.
N1 - Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - The aim of this study was to investigate whether 18F‑DCFPyL PET/CT imaging resulted in a change of decision on treatment management in patients with biochemically recurrent (BCR) prostate cancer. 253 patients with BCR prostate cancer who underwent restaging 18F‑DCFPyL PET/CT were assessed. Two urologists formulated a preferred treatment for each patient before and after knowing the results of the 18F‑DCFPyL PET/CT. In 103/253 cases (40.7%), a preferred treatment change based on the 18F‑DCFPyL PET/CT findings was reported. A positive 18F‑DCFPyL PET/CT (p < 0.001), and positive pathological lymph node status (pN1; p = 0.024) were significant predictors for an intended change of management, whereas a positive surgical margin (p = 0.022) was inversely associated with an intended change of management. It was concluded that, in this study, we found a significant impact of 18F‑DCFPyL PET/CT on the intended management of patients with BCR prostate cancer.
AB - The aim of this study was to investigate whether 18F‑DCFPyL PET/CT imaging resulted in a change of decision on treatment management in patients with biochemically recurrent (BCR) prostate cancer. 253 patients with BCR prostate cancer who underwent restaging 18F‑DCFPyL PET/CT were assessed. Two urologists formulated a preferred treatment for each patient before and after knowing the results of the 18F‑DCFPyL PET/CT. In 103/253 cases (40.7%), a preferred treatment change based on the 18F‑DCFPyL PET/CT findings was reported. A positive 18F‑DCFPyL PET/CT (p < 0.001), and positive pathological lymph node status (pN1; p = 0.024) were significant predictors for an intended change of management, whereas a positive surgical margin (p = 0.022) was inversely associated with an intended change of management. It was concluded that, in this study, we found a significant impact of 18F‑DCFPyL PET/CT on the intended management of patients with BCR prostate cancer.
KW - F‑DCFPyL PET/CT
KW - PSMA
KW - biochemical recurrence
KW - change of management
KW - prostate cancer
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85109348443&origin=inward
UR - http://www.scopus.com/inward/record.url?scp=85109348443&partnerID=8YFLogxK
U2 - https://doi.org/10.1007/s13629-021-00330-1
DO - https://doi.org/10.1007/s13629-021-00330-1
M3 - Article
SN - 2211-3037
VL - 11
SP - 89
EP - 100
JO - Tijdschrift voor urologie
JF - Tijdschrift voor urologie
IS - 5
ER -